Please login to the form below
Seattle Genetics
This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.
Seattle Genetics wins FDA priority review for oral HER2 drug
If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... Seattle is seeking approval for tucatinib in combination
Latest news
-
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck &Co/MSD’s Keytruda in first-line ... line setting," said Roger Dansey, chief medical
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
-
J&J taps TARIS Biomedical for novel bladder cancer technology
However, J&J is not alone in the bladder cancer market. Seattle Genetics and Astellas claimed approval in the US for Padcev (enfortumab vedotin) last week, as a later-line therapy
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Plans to expand use into earlier bladder cancer treatment. Seattle Genetics and Astellas have claimed approval in the US for Padcev, an antibody-drug conjugate (ADC), as a later-line therapy ... That would drive a sizeable step up in Seattle’s turnover,
-
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
Also on the horizon is Seattle Genetics’ oral HER2 drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus Roche’s chemotherapy Xeloda (capecitabine) ... Seattle also has ambition to extend tucatinib into
More from news
Approximately 11 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals in June 2015
NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
-
Deal Watch table for September 2014
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
-
Douglas Williams named president and CEO of Codiak
These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
-
VentiRx appoints James Kyle Bryan as chief medical officer
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
